Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|October 13, 2014
The Impact of Neuroendocrine Tumor Heterogeneity During Disease Progression
Author(s)David S. Klimstra, MD
David S. Klimstra, MD, discusses the impact of tumor heterogeneity during disease progression. This was the topic of a talk given by Oliver G. McDonald, MD, PhD, at the 2014 NANETS Symposium.
Advertisement
Clinical Pearls
David S. Klimstra, MD, chair, Department of Pathology, Memorial Sloan Kettering Cancer Center, discusses the impact of tumor heterogeneity during disease progression. This was the topic of a talk given by Oliver G. McDonald, MD, PhD, from Vanderbilt University Medical Center, at the 2014 NANETS Symposium.
- There is tumor heterogeneity in NET biology between the primary and metastases and/or between sites of metastases. The genetics of this heterogeneity is not yet understood.
- There is clonal evolution in the development of metastases.
- The epigenetic evolution of a tumor is site-specific. This is slightly discouraging, because shutting off the driving gene could be much more difficult if the driving pathway has been modified in metastatic sites.
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Advisory panel backs Galleri blood test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5